CI - Cigna Corporation
Cigna Group (NYSE: CI - Get Free Report) and Quest Diagnostics (NYSE: DGX - Get Free Report) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability. Insider and Institutional Ownership 87.0% of Cigna
On October 15, 2026, The Cigna Group (CI) shares rose 3.2% to $298.81, reflecting a positive momentum in the stock amidst a trading range of $239.51 to $311.34
Jobs Growth: Slower but Steady Over time, growth in real GDP roughly equals the combination of productivity growth and labor force growth, and employment growth tracks the labor force (exhibit 1). When the business cycle rolls over, recessions push unemployment higher, and then recoveries bring it back down.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BLOOMFIELD, Conn., Oct. 9, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its third quarter 2026 financial results on Thursday, November 5, 2026, and will host a conference call the same day.
Titleist Asset Management LLC bought a new position in Cigna Group (NYSE: CI) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,547 shares of the health services provider's stock, valued at approximately $964,000. Other institutional investors also
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
By connecting information about each person's health, care and coverage, Health Sense℠ helps people receive continuous personalized support, make informed decisions and act sooner Projected to reduce inefficient health care spending by 10% by 2030, improving affordability for employers and customers alike. Watch a demonstration of the new Health Sense customer experience.
Cigna is rated a 'Strong Buy' for its compelling value, robust earnings growth, and capital returns at a forward P/E of 8.9x. CI posted strong Q2 2026 results, raised full-year EPS guidance, and targets 10–14% annual EPS growth through 2030, driven by AI and specialty pharmacy. CI's asset-light model, expanding specialty pharma presence, and aggressive share buybacks support high-teens total return potential annually.
The Cigna Group (CI) Analyst/Investor Day Transcript
Cigna Group NYSE: CI reaffirmed its 2026 outlook and outlined a long-term strategy centered on complex care, technology-enabled personalization and disciplined capital deployment at its 2026 Investor Day.
The Cigna Group (CI) shares are experiencing a significant decline following the company's reaffirmation of its FY26 guidance during its Investor Day. Investors
Cigna said on Wednesday it will invest $3 billion as part of a multi-year program to focus on modernizing processes and streamlining workflows, among others, with AI-enabled insights and tools to drive growth.
Following deliberate portfolio shaping over the last several years, The Cigna Group is strategically positioned where health care costs are concentrating with multiple avenues for growth Announces "Lead to One" vision, unifying all colleagues around delivering personalization at scale to improve affordability and the patient experience Distinct, industry-leading capabilities in complex care, powered by clinical expertise, data, technology and AI Announces $3B multi-year modernization and productivity initiative to fuel performance Reaffirms 2026 full-year financial guidance and provides long-term financial growth target of 10-14% adjusted EPS CAGR through 2030 BLOOMFIELD, Conn., Sept. 30, 2026 /PRNewswire/ -- Today, at its Investor Day, The Cigna Group (NYSE: CI) will outline its strategy to improve affordability and personalization across the health care continuum.
Cigna Group (NYSE: CI - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-three ratings firms that are currently covering the company, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 1 year price target
Cigna Group investors will be looking for more detail on the growth of its specialty pharmacy business under new CEO Brian Evanko.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
We believe that there is nothing more fundamental and reflective of economic health than the employment situation, and the latest data reflects an economy showing persistent growth. After July's disappointing payroll print, the August employment report rebounded strongly.
Building a two-site demonstration laboratory system together with the se miconductor - focused facility in Bengaluru, Hitachi High - Tech aims to strengthen the
CI is expanding AI across care coordination and specialty pharmacy as it seeks to manage elevated healthcare costs and improve access.